Publication:
Superantigens

dc.contributor.authorNicholas W. Stowen_US
dc.contributor.authorRichard Douglasen_US
dc.contributor.authorPongsakorn Tantilipikornen_US
dc.contributor.authorJean Silvain Lacroixen_US
dc.contributor.otherNorth Shore Hospitalen_US
dc.contributor.otherAuckland City Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHopitaux universitaires de Geneveen_US
dc.date.accessioned2018-09-24T09:27:36Z
dc.date.available2018-09-24T09:27:36Z
dc.date.issued2010-06-01en_US
dc.description.abstractSuperantigens (SAgs) are derived from diverse sources, including bacteria, viruses, and human hepatic tissue. SAgs initially cause lymphocyte activation but then result in clonal deletion and anergy, leading to immune tolerance. They can also act as superallergens by stimulating a broad spectrum of mast cells and basophils in patients with allergic conditions. The newly described staphylococcal SAg-like proteins subvert innate immune function by several mechanisms, which are distinct from SAgs' effects on lymphocytes and other acquired immune processes. There is mounting evidence to suggest that SAgs play a role in the pathophysiology of inflammatory airway disease. The pathophysiologic role of SAg-like proteins awaits clarification. © 2010 Elsevier Inc.en_US
dc.identifier.citationOtolaryngologic Clinics of North America. Vol.43, No.3 (2010), 489-502en_US
dc.identifier.doi10.1016/j.otc.2010.02.008en_US
dc.identifier.issn00306665en_US
dc.identifier.other2-s2.0-77953525403en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/29648
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953525403&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSuperantigensen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953525403&origin=inwarden_US

Files

Collections